ArticleAging2019
Erythropoietin prevents dementia in hemodialysis patients: a nationwide population-based study.
Article in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Therapeutic and biomarker potential of erythropoietin in neurodegenerative diseases: a systematic review.BMC neurology · 2026Pooled it
- Cognitive Impairment in End Stage Renal Disease Patients Undergoing Hemodialysis: Markers and Risk Factors.International journal of environmental research and public health · 2022Pooled it
- Interventions to improve cognitive performance in chronic kidney disease: A scoping review.PloS one · 2025Article
- Role of erythropoietin in the treatment of Alzheimer's disease: the story so far.Annals of medicine and surgery (2012) · 2024Review
- The Role of Plasma Neurofilament Light Protein for Assessing Cognitive Impairment in Patients With End-Stage Renal Disease.Frontiers in aging neuroscience · 2021Article
- Lack of association between erythropoietin treatment and risk of depression in patients with end-stage kidney disease on maintenance dialysis: a nationwide database study in Taiwan.Therapeutic advances in chronic disease · 2021Article
- Erythropoietin and Non-Erythropoietic Derivatives in Cognition.Frontiers in pharmacology · 2021Review
- Hyperuricemia might be an early manifestation of undiagnosed adult leukemia in a population-based cohort study.BioMedicine · 2020Article
- Effects and Mechanisms of Five Psoralea Prenylflavonoids on Aging-Related Diseases.Oxidative medicine and cellular longevity · 2020Review
- How Do You Feel Now? The Salience Network Functional Connectivity in End-Stage Renal Disease.Frontiers in neuroscience · 2020Article
- Predictors of cognitive impairment and its association with mortality in maintenance hemodialysis patients: A prospective follow-up study.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietic medications such as including erythropoietin (EPO) are known to be neuroprotective and to correlate with improved cognitive functions. However, it is not known whether supplementation with EPO reduces the risk of dementia in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). Here, we determined whether EPO levels correlate with the incidence of different dementia subtypes, including Alzheimer's disease (AD), vascular dementia (VaD), and unspecified dementia (UnD), and whether such associations vary with annual cumulatively defined daily doses (DDDs) of EPO for ESRD patients receiving HD. This retrospective study included data from 43,906 adult ESRD patients who received HD between 1999 and 2010. Using hazard ratios and Cox regression models, we found that patients receiving EPO had a 39% lower risk of general dementia than those in the non-EPO group. Similarly, the risks of VaD and UnD was lower for patients in the EPO cohort. The risk of dementia was further reduced in HD patients treated with EPO in combination with iron. Our results suggest that the use of EPO medications in HD patients is associated with a reduced risk of VaD and UnD, but not AD, regardless of whether EPO is used alone or in combination with iron.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.